Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Aligos Therapeutics's share price for the quarter that ended in Mar. 2026 was €6.4. Aligos Therapeutics's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 6.19 Mil. Therefore, Aligos Therapeutics's market cap for the quarter that ended in Mar. 2026 was €39.60 Mil.
Aligos Therapeutics's quarterly market cap
increased
from Sep. 2025 (€49.54 Mil) to Dec. 2025 (€49.73 Mil) but then
declined
from Dec. 2025 (€49.73 Mil) to Mar. 2026 (€39.60 Mil).
Aligos Therapeutics's annual market cap
increased
from Dec. 2023 (€43.56 Mil) to Dec. 2024 (€149.15 Mil) but then
declined
from Dec. 2024 (€149.15 Mil) to Dec. 2025 (€49.73 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Aligos Therapeutics's Enterprise Value for Today is €-13.42 Mil.
Aligos Therapeutics (STU:5WK0) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Aligos Therapeutics Market Cap Related Terms
Aligos Therapeutics Market Cap Historical Data
* Premium members only.
The historical data trend for Aligos Therapeutics's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:5WK0 vs SNTI, NTRB, CRVO: Market Cap Comparison
For the Biotechnology subindustry, Aligos Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aligos Therapeutics Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aligos Therapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where Aligos Therapeutics's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Aligos Therapeutics's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aligos Therapeutics (STU:5WK0) has a Market Cap of €30.97 Mil as of Jul. 20, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Aligos Therapeutics and its competitors. According to the industry distribution chart, Aligos Therapeutics ranks #970 out of 1423 companies in the Biotechnology industry, placing it in the top 68.2%.
Is Aligos Therapeutics' Market Cap too high?
Aligos Therapeutics' current Market Cap is €30.97 Mil. Based on the distribution chart, Aligos Therapeutics ranks #970 out of 1423 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Aligos Therapeutics has a GF Score™ of 32/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aligos Therapeutics' Market Cap compare to SNTI and NTRB?
According to the Biotechnology industry distribution chart, Aligos Therapeutics ranks #970 out of 1423 companies for Market Cap. This places Aligos Therapeutics in the lower half of its industry. The industry median Market Cap is 113.11. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 113.11, based on 1,423 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Aligos Therapeutics and its competitors. For the Biotechnology industry, the median Market Cap is 113.11 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aligos Therapeutics's current Market Cap is €30.97 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aligos Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Aligos Therapeutics (STU:5WK0) is currently considered Significantly Overvalued. The stock's GF Value™ is €2.38, compared to a current price of €4.96 — trading 108.4% above its estimated fair value. The current Market Cap is €30.97 Mil. Aligos Therapeutics' overall GF Score™ is 32/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Aligos Therapeutics (STU:5WK0), the current Market Cap is €30.97 Mil as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aligos Therapeutics (STU:5WK0) Overvalued in 2026?
Based on GuruFocus' analysis, Aligos Therapeutics stock appears to be overvalued.
The current stock price of €4.96 is trading 108.4% above its estimated GF Value™ of €2.38.
GuruFocus considers Aligos Therapeutics to be Significantly Overvalued.
Key valuation signals for STU:5WK0:
Market Cap: €30.97 Mil
GF Value™: €2.38 vs. price of €4.96 (108.4% above fair value)
No single metric tells the full story. See the STU:5WK0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.
32GF Score
Get the complete analysis for STU:5WK0
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:5WK0 has been successfully added to your 
